- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Jhalak Dholakia, MD | Authors
Jhalak Dholakia, MD, Spotlights Ongoing Trial of Neoadjuvant Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
May 03, 2022
An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
Jhalak Dholakia, MD, Highlights Promise of Neoadjuvant Carboplatin/Mirvetuximab Soravtansine in Advanced Ovarian Cancer
March 19, 2022
Jhalak Dholakia, MD, discusses the promising neoadjuvant combination of of carboplatin and mirvetuximab soravtansine in folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.
Advertisement
Advertisement